UnitedHealth Shares Surge as Q2 Results Top Forecasts and Guidance Raised
Strong cost control and Optum performance drive recovery.
Strong cost control and Optum performance drive recovery.
The company raised full-year guidance and remains on track for its first $100 billion revenue year.
Despite beating Q2 estimates and lifting 2026 guidance, Elevance Health saw margins compress sharply. Core operating margin fell to 3.5% on higher medical costs.
$400M pre-tax hit in Q2 as ACA subsidies expire.
enGene is reducing its workforce by ~50% and has stopped patient enrollment in three additional LEGEND trial cohorts to preserve cash while focusing on its pivotal data and planned BLA filing.
Regenxbio’s DMD gene therapy showed strong results, boosting muscle protein and safety, moving closer to FDA approval.